Middle East And Africa Multiple Sclerosis Treatment Market
Размер рынка в млрд долларов США
CAGR : %
Прогнозируемый период |
2022 –2029 |
Размер рынка (базовый год) |
USD 235.54 Million |
Размер рынка (прогнозируемый год) |
USD 348.00 Million |
CAGR |
|
Основные игроки рынка |
>Рынок лечения рассеянного склероза на Ближнем Востоке и в Африке по типу (клинически изолированный синдром (CIS), рецидивирующе-ремиттирующий РС (RRMS), первично-прогрессирующий РС (PPMS), вторично-прогрессирующий РС (SPMS)), лечение (лекарства, терапия стволовыми клетками, физиотерапия , плазмаферез, другие), класс лекарств (иммуномодуляторы, иммунодепрессанты, интерфероны, другие), диагностика (магнитно-резонансная томография (МРТ), простые электростимуляционные тесты, люмбальная пункция, другие), способ введения (пероральный, парентеральный, другие), конечные пользователи (больницы, специализированные клиники, уход на дому, другие), канал сбыта (больничная аптека, розничная аптека, интернет-аптека, другие) — тенденции отрасли и прогноз до 2029 г.
Анализ и размер рынка
По данным Национального общества рассеянного склероза, рассеянным склерозом страдают около 1 миллиона человек в Соединенных Штатах и 2,3 миллиона человек во всем мире. Каждый год число людей, у которых диагностирован рассеянный склероз, растет, что требует разработки новых лекарств, которые более эффективны и имеют меньше побочных эффектов. Правительства и неправительственные организации в развитых и развивающихся странах наращивают усилия по повышению осведомленности о рассеянном склерозе и выделяют значительные средства на исследования и разработку лекарственных препаратов.
По данным анализа Data Bridge Market Research, рынок лечения рассеянного склероза в 2021 году оценивался в 235,54 млн долларов США, а к 2029 году, как ожидается, достигнет 348,00 млн долларов США, что соответствует среднегодовому темпу роста (CAGR) в 5,00% в прогнозируемый период с 2022 по 2029 год. Отчет о рынке, подготовленный командой Data Bridge Market Research, включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ линейки препаратов, анализ цен и нормативно-правовую базу.
Область отчета и сегментация рынка
Отчет Метрика |
Подробности |
Прогнозируемый период |
2022-2029 |
Базовый год |
2021 |
Исторические годы |
2020 (Можно настроить на 2019 - 2014) |
Количественные единицы |
Доход в млн. долл. США, объемы в единицах, цены в долл. США |
Охваченные сегменты |
По типу (клинически изолированный синдром (КИС), рецидивирующе-ремиттирующий РС (РРРС), первично-прогрессирующий РС (ППРС), вторично-прогрессирующий РС (ВПРС)), лечению (лекарства, терапия стволовыми клетками, физиотерапия, плазмаферез, другие), классу лекарств (иммуномодуляторы, иммунодепрессанты, интерфероны, другие), диагнозу (магнитно-резонансная томография (МРТ), простые электростимуляционные тесты, люмбальная пункция, другие), способу введения (перорально, парентерально, другие), конечным пользователям (больницы, специализированные клиники, уход на дому, другие), каналу распространения (больничная аптека, розничная аптека, интернет-аптека, другие) |
Страны, охваченные |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Hikma Pharmaceuticals PLC (UK), Merck KGaA (Germany) |
Market Opportunities |
|
Market Definition
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease that affects spinal cord and brain nerve cells, causing demyelination, axonal transection, and neurodegeneration. Injectable, oral, and infused medications, muscle relaxants, antidepressants, and physical therapy are some of the most widely utilized therapies. Interferon-beta and glatiramer acetate are injectable therapies that are given under the skin or into the muscle; oral medications include teriflunomide, dimethyl fumarate, and cladribine; and intravenous infusion treatments include ocrelizumab, alemtuzumab and natalizumab.
Middle East and Africa Multiple Sclerosis Treatment Market Dynamics
Drivers
- Increasing prevalence of multiple sclerosis
The rising prevalence of multiple sclerosis is a primary driver of the multiple sclerosis treatment market's growth. Relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) are the types of multiple sclerosis and their high prevalence rate will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of multiple sclerosis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the multiple sclerosis treatment market. Additionally, high disposable income and increase in the development of innovative monoclonal antibodies, immunosuppressants, immunomodulators, and interferons will expand the multiple sclerosis treatment market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the multiple sclerosis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the multiple sclerosis treatment market during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of multiple sclerosis will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the multiple sclerosis treatment market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Middle East and Africa multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Multiple sclerosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Middle East and Africa Multiple Sclerosis Treatment Market
С момента своего появления в декабре 2019 года вирус COVID-19 распространился почти на все страны планеты, что побудило Всемирную организацию здравоохранения (ВОЗ) объявить его чрезвычайной ситуацией в области общественного здравоохранения. Из-за финансового кризиса и задержки в предоставлении специализированной медицинской помощи при приоритетном лечении, связанном с COVID-19, системы здравоохранения во всем мире были серьезно нарушены после пандемии коронавируса. Пациенты не могли видеть свои контрольные точки по разным причинам, включая трудности с доступом к врачу, страх передачи инфекции, невозможность продолжать терапию и основные процедуры из-за ограничений, связанных с пандемией. Такие соображения могут оказать негативное влияние на рынок рассеянного склероза на Ближнем Востоке и в Африке в последние месяцы.
Недавнее развитие
- В августе 2020 года компания Novartis объявила о запуске препарата Kesimpta (ofatumumab), который будет одобрен Управлением по контролю за продуктами и лекарствами США (FDA). Это первая и единственная самостоятельно применяемая целевая терапия B-клеток для людей, страдающих рецидивирующим рассеянным склерозом. Kesimpta сочетает в себе мощную эффективность с приемлемым профилем безопасности и может применяться самостоятельно в домашних условиях, заполняя критический пробел в лечении рецидивирующих форм рассеянного склероза (РМС).
Масштаб рынка лечения рассеянного склероза на Ближнем Востоке и в Африке
Рынок лечения рассеянного склероза на Ближнем Востоке и в Африке сегментирован на основе типа, класса препарата, лечения, диагностики, пути введения, конечных пользователей и канала сбыта. Рост среди этих сегментов поможет вам проанализировать сегменты с незначительным ростом в отраслях и предоставить пользователям ценный обзор рынка и рыночные идеи, которые помогут им принимать стратегические решения для определения основных рыночных приложений.
Тип
- Клинически изолированный синдром (КИС)
- Рецидивирующе-ремиттирующий рассеянный склероз (РРРС)
- Первично-прогрессирующий рассеянный склероз (ППРС)
- Вторично-прогрессирующий рассеянный склероз (ВПРС)
Уход
- Лекарства
- Инъекционные терапии
- Интерферон-бета
- Глатирамера ацетат
- Пероральные препараты
- Диметилфумарат
- Терифлуномид
- Кладрибин
- Внутривенные инфузионные процедуры
- Окрелизумаб
- Натализумаб
- Алемтузумаб
- Терапия стволовыми клетками
- Физиотерапия
- Плазменный обмен
- Другие
Класс наркотиков
- Иммуномодуляторы
- Иммунодепрессанты
- Интерфероны
- Другие
Диагноз
- Магнитно-резонансная томография (МРТ)
- Простые тесты электростимуляции
- Люмбальная пункция
- Другие
Путь введения
- Оральный
- Парентеральный
- Другие
Конечные пользователи
- Больницы
- Специализированные клиники
- Уход на дому
- Другие
Канал распространения
- Больничная аптека
- Розничная аптека
- Интернет-аптека
- Другие
Региональный анализ/информация о рынке лечения рассеянного склероза на Ближнем Востоке и в Африке
Проанализирован рынок лечения рассеянного склероза на Ближнем Востоке и в Африке, а также предоставлены сведения о размерах рынка и тенденциях по странам, типу, лечению, классу препарата, диагнозу, способу введения, конечным пользователям и каналу сбыта, как указано выше.
Страны, охваченные отчетом о рынке лечения рассеянного склероза на Ближнем Востоке и в Африке: Саудовская Аравия, ОАЭ, Южная Африка, Египет, Израиль, остальные страны Ближнего Востока и Африки (БВА) как часть Ближнего Востока и Африки (БВА).
Ожидается, что в прогнозируемый период 2022–2029 гг. в регионе Ближнего Востока и Африки будет наблюдаться рост в Южной Африке в связи с повышением осведомленности о рассеянном склерозе и ростом расходов на здравоохранение в этом регионе.
Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости сверху и снизу, технические тенденции и анализ пяти сил Портера, тематические исследования, являются некоторыми из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность брендов Ближнего Востока и Африки и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние внутренних тарифов и торговых путей.
Конкурентная среда и анализ доли рынка лечения рассеянного склероза на Ближнем Востоке и в Африке
Конкурентная среда рынка лечения рассеянного склероза на Ближнем Востоке и в Африке содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, присутствие на Ближнем Востоке и в Африке, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта, доминирование в применении. Приведенные выше данные относятся только к фокусу компаний, связанному с рынком лечения рассеянного склероза на Ближнем Востоке и в Африке.
Некоторые из основных игроков, работающих на рынке лечения рассеянного склероза на Ближнем Востоке и в Африке:
- F. Hoffmann-La Roche Ltd. (Швейцария)
- Mylan NV (США)
- Teva Pharmaceutical Industries Ltd. (Ирландия)
- Санофи (Франция)
- Pfizer Inc. (США)
- GlaxoSmithKline plc (Великобритания)
- Новартис АГ (Швейцария)
- Bayer AG (Германия)
- Eli Lilly and Company (США)
- Merck KGaA (Германия)
- Hikma Pharmaceuticals PLC (Великобритания)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: REGULATIONS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS
5.1.2 EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITY IN MULTIPLE SCLEROSIS TREATMENT
5.1.3 RISING GOVERNMENT INITIATIVES
5.1.4 INCREASING NEED FOR BETTER MULTIPLE SCLEROSIS TREATMENT OPTIONS
5.2 RESTRAINTS
5.2.1 PATENT EXPIRY OF DRUGS
5.2.2 HIGH COST OF TREATMENT
5.3 OPPORTUNITIES
5.3.1 INCREASING AWARENESS FOR MULTIPLE SCLEROSIS TREATMENT
5.3.2 INTRODUCTION OF DISEASE-MODIFYING DRUGS
5.3.3 PRESENCE OF STRONG PIPELINE DRUGS
5.4 CHALLENGES
5.4.1 INCREASING SIDE EFFECT OF MULTIPLE SCLEROSIS MEDICATION
5.4.2 LIMITATIONS IN MULTIPLE SCLEROSIS THERAPY
6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN HEALTHCARE INDUSTRY
6.1 OVERVIEW
6.2 PRICE IMPACT
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 STRATEGIC DECISIONS FOR MANUFACTURERS
6.6 CONCLUSION
7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.1 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)
7.2 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
7.3 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
7.4 SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES)
8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 PREVENTIVE THERAPIES
8.2.1 ORAL MEDICATION
8.2.1.1 TECFIDERA
8.2.1.2 GILENYA
8.2.1.3 AUBAGIO
8.2.1.4 MAVENCLAD
8.2.1.5 MAYZENT
8.2.1.6 VUMERITY
8.2.1.7 OTHERS
8.2.2 INJECTABLE MEDICATION
8.2.2.1 INTERFERON BETA-1A
8.2.2.1.1 AVONEX
8.2.2.1.2 REBIF
8.2.2.1.3 OTHERS
8.2.2.2 GLATIRAMER ACETATE
8.2.2.2.1 COPAXONE
8.2.2.2.2 GLATOPA
8.2.2.2.3 OTHERS
8.2.2.3 INTERFERON BETA-1B
8.2.2.3.1 BETASERON
8.2.2.3.2 EXTAVIA
8.2.2.4 PLEGRIDY/PEGINTERFERON BETA-1A
8.2.2.5 CHEMOTHERAPY DRUG
8.2.2.6 MONOCLONAL ANTIBODIES
8.2.3 INFUSED MEDICATION
8.2.3.1 TYSABRI
8.2.3.2 OCREVUS
8.2.3.3 LEMTRADA
8.2.3.4 MITOXANTRONE
8.2.3.5 NOVANTRONE
8.2.3.6 OTHERS
8.2.4 HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
8.3 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS
8.3.1 CORTICOSTEROIDS
8.3.1.1 ORAL PREDNISONE
8.3.1.2 METHYLPREDNISOLONE
8.3.1.3 DEXAMETHASONE
8.3.1.4 PREDNISOLONE
8.3.1.5 BETAMETHASONE
8.3.1.6 OTHERS
8.3.2 IMMUNOSUPPRESSANTS
8.3.2.1 AZATHIOPRINE
8.3.2.2 CYCLOPHOSPHAMIDE
8.3.2.3 METHOTREXATE
8.3.2.4 MITOXANTRONE
8.3.2.5 OTHERS
8.3.3 ADRENOCORTICOTROPIC HORMONE
8.3.4 PLASMAPHERESIS
8.3.5 INTRAVENOUS IMMUNOGLOBULIN
8.3.6 OTHERS
8.4 SYMPTOMATIC THERAPIES
8.4.1.1 MUSCLE RELAXANTS
8.4.1.1.1 LIORESAL
8.4.1.1.2 ZANAFLEX
8.4.1.1.3 OTHERS
8.4.1.2 FATIGUE MEDICATIONS
8.4.1.2.1 GOCOVRI
8.4.1.2.2 OSMOLEX
8.4.1.2.3 PROVIGIL
8.4.1.2.4 RITALIN
8.4.1.2.5 OTHERS
8.4.1.3 PHYSIOTHERAPY
8.4.1.4 LAXATIVES
9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.2.1 TECFIDERA
9.2.2 GILENYA
9.2.3 AUBAGIO
9.2.4 AVONEX
9.2.5 TYSABRI
9.2.6 REBIF
9.2.7 COPAXONE
9.2.8 8 BETASERON
9.2.9 AMPYRA/FAMPYRA
9.2.10 OTHERS
9.3 GENERIC
10 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 PARENTERAL
10.3.1 INTRAVENOUS
10.3.2 SUBCUTANEOUS
10.3.3 OTHERS
11 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 HOMECARE
11.4 SPECIALTY CENTERS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.2.1 RETAIL PHARMACY
12.2.2 HOSPITAL PHARMACY
12.3 DIRECT TENDER
13 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST & AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 UAE
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST & AFRICA
14 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT
16 COMPANY PROFILES
16.1 BIOGEN
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 NOVARTIS AG
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 MERCK KGAA
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 F. HOFFMANN-LA ROCHE LTD
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 ACORDA THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 1.7.4 RECENT DEVELOPMENT
16.8 ADAMAS PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 AMNEAL PHARMACEUTICALS LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 BAYER AG
16.10.1 COMPANY SNAPSHOT
16.10.2 1.10.2REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 HIKMA PHARMACEUTICALS PLC
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 LANNETT
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MALLINCKRODT
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 MYLAN N.V.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 PFIZER INC.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENTS
16.18 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Список таблиц
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE
TABLE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 1 MIDDLE EAST AND AFRICA RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 62 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 63 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64 SAUDI ARABIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 65 SAUDI ARABIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 66 SAUDI ARABIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67 SAUDI ARABIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 68 SAUDI ARABIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 69 SAUDI ARABIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70 SAUDI ARABIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 71 SAUDI ARABIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 72 SAUDI ARABIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73 SAUDI ARABIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 74 SAUDI ARABIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 75 SAUDI ARABIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76 SAUDI ARABIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 77 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 78 SAUDI ARABIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 79 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 80 SAUDI ARABIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 81 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 82 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 83 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 84 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 85 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 86 SOUTH AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 87 SOUTH AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88 SOUTH AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 89 SOUTH AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 90 SOUTH AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 91 SOUTH AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92 SOUTH AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 93 SOUTH AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94 SOUTH AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95 SOUTH AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 96 SOUTH AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 97 SOUTH AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 99 SOUTH AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 100 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101 SOUTH AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 102 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 103 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 104 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 105 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 106 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107 UAE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 108 UAE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 109 UAE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 110 UAE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 111 UAE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 112 UAE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 113 UAE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 114 UAE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 115 UAE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116 UAE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 117 UAE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 118 UAE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 119 UAE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 120 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 121 UAE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 122 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 123 UAE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 124 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 125 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 126 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 127 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 128 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 129 ISRAEL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 130 ISRAEL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131 ISRAEL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 132 ISRAEL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 133 ISRAEL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134 ISRAEL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 135 ISRAEL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 136 ISRAEL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 137 ISRAEL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 138 ISRAEL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 139 ISRAEL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 140 ISRAEL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 141 ISRAEL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 142 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 143 ISRAEL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 144 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 145 ISRAEL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 147 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 148 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 149 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 150 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 151 KUWAIT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152 KUWAIT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 153 KUWAIT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 154 KUWAIT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155 KUWAIT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 156 KUWAIT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 157 KUWAIT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 158 KUWAIT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 159 KUWAIT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 160 KUWAIT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 161 KUWAIT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 162 KUWAIT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 163 KUWAIT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 164 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 165 KUWAIT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 166 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 167 KUWAIT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 168 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 169 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 170 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 171 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 172 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 173 EGYPT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 174 EGYPT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 175 EGYPT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 176 EGYPT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 177 EGYPT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 178 EGYPT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 179 EGYPT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 180 EGYPT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 181 EGYPT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 182 EGYPT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 183 EGYPT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 184 EGYPT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 185 EGYPT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 186 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 187 EGYPT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 188 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 189 EGYPT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 190 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 191 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 192 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 193 REST OF MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
Список рисунков
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 10 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 11 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN 2020 & 2027
FIGURE 12 PIPELINE ANALYSIS
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET
FIGURE 14 MULTIPLE SCLEROSIS PREVALENCE
FIGURE 15 MULTIPLE SCLEROSIS PREVALENCE BY GENDER
FIGURE 16 PIPELINE BY DEVELOPMENT PHASE, 2019 VERSUS 2018
FIGURE 17 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019
FIGURE 18 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019-2027 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2020-2027)
FIGURE 20 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019
FIGURE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)
FIGURE 24 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, 2019
FIGURE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 28 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 32 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, 2019
FIGURE 34 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 36 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 38 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 39 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 40 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 42 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 43 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 44 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 45 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 46 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.